



03 Co


ATTORNEY DOCKET NO. L0461/7112 (JRV/MXA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Obata, Y.  
Serial No: 09/835,992  
Filed: April 17, 2001  
For: Isolated Nucleic Acid Molecules Associated With Gastric Cancer  
And Methods For Diagnosing And Treating Gastric Cancer  
Examiner: Not Yet Assigned  
Art Unit: Not Yet Assigned

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner of Patents, Washington, D.C. 20231 on the \_\_\_ day of July, 2001.

  
Paula Fairweather

Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:


Transmitted herewith for filing are the following:

- ☒ Statement Pursuant to 37 CFR 1.825(a) and (b)
- ☒ Copy of Notification to Comply Requirements
- ☒ Substitute paper copy of the Sequence Listing
- ☒ Substitute Computer Readable Form (CRF) copy of the Sequence Listing
- ☒ Return Receipt Postcard


If the enclosed papers are considered incomplete, the mailroom and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

Please charge any deficiencies or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
John R. Van Amsterdam, Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
(617) 720-3500

Attorney Docket No.: L0461/7112  
Date: July 19, 2001  
x07/21/01x



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/835,992	04/17/2001	Yuichi Obata	L0461/7112 (JRV)

CONFIRMATION NO. 6680

23628

WOLF GREENFIELD & SACKS, PC  
FEDERAL RESERVE PLAZA  
600 ATLANTIC AVENUE  
BOSTON, MA 02210-2211

FORMALITIES LETTER



\*OC000000006095653\*

Date Mailed: 05/21/2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



# 3

ATTORNEY DOCKET NO. L0461/7112 (JRV/MXA)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Obata, Y.  
Serial No: 09/835,992  
Filed: April 17, 2001  
For: Isolated Nucleic Acid Molecules Associated With Gastric Cancer  
And Methods For Diagnosing And Treating Gastric Cancer  
Examiner: Not Yet Assigned  
Art Unit: Not Yet Assigned

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on the \_\_\_th day of July, 2001.

Paula Fairweather

Commissioner for Patents  
Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.825(a) and (b)

Sir:

This statement is made pursuant to 37 CFR 1.825(a) and (b). Applicant submits herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with formatting requirements for the sequence listing. Carriage returns have been added in the necessary locations to comply with the formatting requirements. In addition, SEQ ID NO:42 and SEQ ID NO: 58 each had one typographical error in the description of the sequence length corrected. No new matter has been added.

Applicant's attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contains new matter.

Respectfully submitted,

John R. Van Amsterdam, Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
(617) 720-3500

Attorney Docket No.: L0461/7122  
Date: July 19, 2001  
x07/21/01x

548830.1